File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: HIF-1α blockade enhances the therapeutic efficacy of hypoxia for the treatment of hepatocellular carcinoma (HCC)

TitleHIF-1α blockade enhances the therapeutic efficacy of hypoxia for the treatment of hepatocellular carcinoma (HCC)
Authors
Issue Date2007
PublisherAmerican Association for Cancer Research.
Citation
The 98th Annual Meeting of the American Association for Cancer Research (AACR), Los Angeles, CA., 14–18 April 2007. In Cancer Research, 2007, v. 67 n. 9S, p. 4803 How to Cite?
AbstractBackground and Objective: Transarterial embolization (TAE) is the major alternative for the treatment of non-resectable hepatocellular carcinoma (HCC). Although the hypoxic condition generated by hepatic artery blockade could induce tumor cell death, hypoxia-related angiogenesis and subsequent tumor re-growth might lead to treatment failure. Therefore, we designed the present study to investigate whether suppression of the activity of HIF-1α, a key player in hypoxia-induced angiogenesis, could enhance the therapeutic efficacy of hypoxia. Materials and Methods: In vitro, hypoxia was induced by culturing the tumor cells with 0.1% O2. YC-1, a HIF-1α blocker, was administered to the tumor cells at different concentrations under hypoxic condition. The proliferation and viability of the cells were determined by MTT assay and Annexin-V labeling, respectively. Molecular mechanism related to HIF-1α was determined by Western blot and luciferase promoter assay. In vivo, an orthotopic HCC model was generated by injection of tumor cells into the left lobe of the rat liver. Hypoxia was induced by hepatic artery ligation (HAL). YC-1 was administered through intra-tumoral injection right after hepatic artery ligation. Survival time was recorded and the histology of tumor tissue was studied. Results: In vitro, YC-1 administration decreased the viability of tumor cells but did not cause any change in the number of apoptotic cells. Hypoxia upregulated the expression of HIF-1α, which could be suppressed by YC-1 administration. The suppressive effect of YC-1 on HIF-1α could be blocked by overexpression of murine double minute 2 (MDM2), a potential upstream molecule of HIF-1α, and YC-1 affected MDM2 expression at a transcriptional level. In vivo, HAL stimulated HIF-1α upregulation in the tumor tissue with a peak level at 24 hr. Administration of YC-1 significantly prolonged the survival of tumor-bearing rats. Both HAL and HAL combined with YC-1 induced tumor tissue necrosis. YC-1 administration decreased the number of HIF-1α+ cells as well as vWF+ cells, which is a marker for angiogenesis in the tumor tissue. In addition, MDM2 mRNA level was downregulated in the combined treatment group, which was consistent with the in vitro results. Conclusion: The present study revealed that blockade of HIF-1α-related pathway could enhance the efficacy of hypoxia for the treatment of HCC. YC-1 achieved anti-HIF-1α effects through MDM2 dependent pathways.
Persistent Identifierhttp://hdl.handle.net/10722/108557
ISSN
2023 Impact Factor: 12.5
2023 SCImago Journal Rankings: 3.468

 

DC FieldValueLanguage
dc.contributor.authorLau, CKen_HK
dc.contributor.authorYang, Zen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-09-26T00:44:37Z-
dc.date.available2010-09-26T00:44:37Z-
dc.date.issued2007en_HK
dc.identifier.citationThe 98th Annual Meeting of the American Association for Cancer Research (AACR), Los Angeles, CA., 14–18 April 2007. In Cancer Research, 2007, v. 67 n. 9S, p. 4803-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/108557-
dc.description.abstractBackground and Objective: Transarterial embolization (TAE) is the major alternative for the treatment of non-resectable hepatocellular carcinoma (HCC). Although the hypoxic condition generated by hepatic artery blockade could induce tumor cell death, hypoxia-related angiogenesis and subsequent tumor re-growth might lead to treatment failure. Therefore, we designed the present study to investigate whether suppression of the activity of HIF-1α, a key player in hypoxia-induced angiogenesis, could enhance the therapeutic efficacy of hypoxia. Materials and Methods: In vitro, hypoxia was induced by culturing the tumor cells with 0.1% O2. YC-1, a HIF-1α blocker, was administered to the tumor cells at different concentrations under hypoxic condition. The proliferation and viability of the cells were determined by MTT assay and Annexin-V labeling, respectively. Molecular mechanism related to HIF-1α was determined by Western blot and luciferase promoter assay. In vivo, an orthotopic HCC model was generated by injection of tumor cells into the left lobe of the rat liver. Hypoxia was induced by hepatic artery ligation (HAL). YC-1 was administered through intra-tumoral injection right after hepatic artery ligation. Survival time was recorded and the histology of tumor tissue was studied. Results: In vitro, YC-1 administration decreased the viability of tumor cells but did not cause any change in the number of apoptotic cells. Hypoxia upregulated the expression of HIF-1α, which could be suppressed by YC-1 administration. The suppressive effect of YC-1 on HIF-1α could be blocked by overexpression of murine double minute 2 (MDM2), a potential upstream molecule of HIF-1α, and YC-1 affected MDM2 expression at a transcriptional level. In vivo, HAL stimulated HIF-1α upregulation in the tumor tissue with a peak level at 24 hr. Administration of YC-1 significantly prolonged the survival of tumor-bearing rats. Both HAL and HAL combined with YC-1 induced tumor tissue necrosis. YC-1 administration decreased the number of HIF-1α+ cells as well as vWF+ cells, which is a marker for angiogenesis in the tumor tissue. In addition, MDM2 mRNA level was downregulated in the combined treatment group, which was consistent with the in vitro results. Conclusion: The present study revealed that blockade of HIF-1α-related pathway could enhance the efficacy of hypoxia for the treatment of HCC. YC-1 achieved anti-HIF-1α effects through MDM2 dependent pathways.-
dc.languageengen_HK
dc.publisherAmerican Association for Cancer Research.-
dc.relation.ispartofCancer Researchen_HK
dc.titleHIF-1α blockade enhances the therapeutic efficacy of hypoxia for the treatment of hepatocellular carcinoma (HCC)en_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLau, CK: lauck@HKUCC-COM.hku.hken_HK
dc.identifier.emailYang, Z: zfyang@hkucc.hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.hkuros128505en_HK
dc.identifier.hkuros145460-
dc.identifier.issnl0008-5472-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats